Related Experiment Videos
Ankylosing spondylitis. Current drug treatment.
Drugs
|October 1, 1992
Summary
Sulfasalazine effectively suppresses ankylosing spondylitis (AS) disease activity, particularly in early stages or with peripheral arthritis. Nonsteroidal anti-inflammatory drugs (NSAIDs) manage flare-ups, while analgesics and muscle relaxants aid chronic cases.
Area of Science:
- Rheumatology
- Pharmacology
Background:
- Ankylosing spondylitis (AS) management relies on drug therapy to alleviate pain and stiffness.
- Current therapeutic strategies involve three main drug categories.
Purpose of the Study:
- To outline the pharmacological approaches for managing ankylosing spondylitis.
- To detail the indications, efficacy, and considerations for different drug classes in AS treatment.
Main Methods:
- Review of drug classes used in ankylosing spondylitis management.
- Analysis of efficacy and safety profiles of sulfasalazine, NSAIDs, analgesics, and corticosteroids.
- Consideration of specific patient populations and clinical scenarios.
Main Results:
- Sulfasalazine is the only disease-modifying drug proven effective in controlled trials for AS, recommended for high disease activity, peripheral arthritis, and early disease.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective for symptom control during flare-ups but carry gastrointestinal and renal risks.
- Analgesics and muscle relaxants are useful for refractory chronic AS, while corticosteroids are used for local injections and specific complications. Special considerations exist for juvenile AS, pregnancy, and surgical patients.
Conclusions:
- Drug selection in AS depends on disease activity, duration, and specific manifestations.
- Sulfasalazine offers disease-modifying effects, while NSAIDs provide symptomatic relief.
- Careful monitoring for side effects and tailored treatment plans are crucial for effective AS management.